

5 October 2023

ASX Market Announcements  
Company Announcements Office  
ASX Limited

Dear Sir/Madam,

**Appendix 3Y – Change of Director’s Interest Notice**

As announced to the ASX on 12 May 2023, Osteopore Limited (**Company**) issued Performance Rights to Mr. Mark Leong, Professor Teoh Swee Hin and Mr. Daniel Ow (together, the **Directors**) (or their respective nominees) under the Company’s employee securities incentive plan on 10 May 2023.

Please find attached Appendix 3Ys *Change of Director’s Interest Notice* for each of the Directors relating to the issue of the Performance Rights.

In relation to the late lodgement of the attached Appendix 3Ys, the Company advises that:

- The Appendix 3Ys were lodged late due to an administrative oversight. The Company arranged for the Appendix 3Ys to be lodged with ASX as soon as practicable upon the Company becoming aware of the oversight described above.
- The Company and its directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B.
- The Company considers that its current practices are adequate to ensure compliance with the relevant ASX Listing Rules. However, the Company intends to further review its procedures to identify and implement any potential improvements.

This announcement has been authorised by the Company Secretary, Kellie Davis.



**Kellie Davis**  
**Company Secretary**

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Osteopore Limited
<b>ABN</b>	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Leong
<b>Date of last notice</b>	7 July 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mark Leong <Avalon Partners Pte Ltd A/C>  Mark Leong is a Director of Avalon Partners Pte Ltd.
<b>Date of change</b>	<ol style="list-style-type: none"> <li>10 May 2023</li> <li>10 May 2023</li> <li>10 May 2023</li> <li>10 May 2023</li> <li>10 May 2023</li> </ol>
<b>No. of securities held prior to change</b>	<b>Mark Leong</b>  187,500 Fully paid ordinary shares 37,500 Listed Options
<b>Class</b>	<ol style="list-style-type: none"> <li>Performance rights (Tranche A)</li> <li>Performance rights (Tranche B)</li> <li>Performance rights (Tranche C)</li> <li>Performance rights (Tranche D)</li> <li>Performance rights (Tranche E)</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1,000,000</li> <li>1,500,000</li> <li>1,750,000</li> <li>2,250,000</li> <li>2,750,000</li> </ol>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	Nil.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>1. 1,000,000 performance rights (Tranche A) issued for nil cash consideration as incentive pursuant to resolution 4(a) of the Notice of General Meeting dated 28 February 2023.</li> <li>2. 1,500,000 performance rights (Tranche B) issued for nil cash consideration as incentive pursuant to resolution 4(a) of the Notice of General Meeting dated 28 February 2023.</li> <li>3. 1,750,000 performance rights (Tranche C) issued for nil cash consideration as incentive pursuant to resolution 4(a) of the Notice of General Meeting dated 28 February 2023.</li> <li>4. 2,250,000 performance rights (Tranche D) issued for nil cash consideration as incentive pursuant to resolution 4(a) of the Notice of General Meeting dated 28 February 2023.</li> <li>5. 2,750,000 performance rights (Tranche E) issued for nil cash consideration as incentive pursuant to resolution 4(a) of the Notice of General Meeting dated 28 February 2023.</li> </ol> <p>Refer to the Notice of General Meeting dated 28 February 2023 for estimated valuation.</p>
<b>No. of securities held after change</b>	<p><b><u>Mark Leong</u></b></p> <p>187,500 Fully paid ordinary shares 37,500 Listed Options</p> <p><b><u>Mark Leong &lt;Avalon Partners Pte Ltd A/C&gt;</u></b></p> <p>1,000,000 performance rights (Tranche A) 1,500,000 performance rights (Tranche B) 1,750,000 performance rights (Tranche C) 2,250,000 performance rights (Tranche D) 2,750,000 performance rights (Tranche E)</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director Performance Rights as approved by shareholders at the Company's General Meeting held on 31 March 2023.

+ See chapter 19 for defined terms.

## **Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

## **Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Osteopore Limited
<b>ABN</b>	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Teoh Swee Hin
<b>Date of last notice</b>	28 April 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	<ol style="list-style-type: none"> <li>1. 10 May 2023</li> <li>2. 10 May 2023</li> <li>3. 10 May 2023</li> <li>4. 10 May 2023</li> <li>5. 10 May 2023</li> </ol>
<b>No. of securities held prior to change</b>	<p><u>Teoh Swee Hin</u></p> <p>Nil</p> <p><u>Citicorp Nominees Pty Limited, as custodian for Professor Teoh Swee Hin</u></p> <p>8,912,886 Fully paid ordinary shares 1,782,577 Listed Options</p>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Performance rights (Tranche A)</li> <li>2. Performance rights (Tranche B)</li> <li>3. Performance rights (Tranche C)</li> <li>4. Performance rights (Tranche D)</li> <li>5. Performance rights (Tranche E)</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1. 100,000</li> <li>2. 150,000</li> <li>3. 175,000</li> <li>4. 225,000</li> <li>5. 275,000</li> </ol>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>1. 100,000 performance rights (Tranche A) issued for nil cash consideration as incentive pursuant to resolution 4(b) of the Notice of General Meeting dated 28 February 2023.</li> <li>2. 150,000 performance rights (Tranche B) issued for nil cash consideration as incentive pursuant to resolution 4(b) of the Notice of General Meeting dated 28 February 2023.</li> <li>3. 175,000 performance rights (Tranche C) issued for nil cash consideration as incentive pursuant to resolution 4(b) of the Notice of General Meeting dated 28 February 2023.</li> <li>4. 225,000 performance rights (Tranche D) issued for nil cash consideration as incentive pursuant to resolution 4(b) of the Notice of General Meeting dated 28 February 2023.</li> <li>5. 275,000 performance rights (Tranche E) issued for nil cash consideration as incentive pursuant to resolution 4(b) of the Notice of General Meeting dated 28 February 2023.</li> </ol> <p>Refer to the Notice of General Meeting dated 28 February 2023 for estimated valuation.</p>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p><b><u>Teoh Swee Hin</u></b></p> <p>100,000 performance rights (Tranche A) 150,000 performance rights (Tranche B) 175,000 performance rights (Tranche C) 225,000 performance rights (Tranche D) 275,000 performance rights (Tranche E)</p> <p><b><u>Citicorp Nominees Pty Limited, as custodian for Professor Teoh Swee Hin</u></b></p> <p>8,912,886 Fully paid ordinary shares 1,782,577 Listed Options</p>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of Director Performance Rights as approved by shareholders at the Company's General Meeting held on 31 March 2023.</p>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<p><b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A
<b>Interest after change</b>	N/A

---

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Osteopore Limited
<b>ABN</b>	65 630 538 957

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Daniel Ow
<b>Date of last notice</b>	13 October 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	<ol style="list-style-type: none"> <li>1. 10 May 2023</li> <li>2. 10 May 2023</li> <li>3. 10 May 2023</li> <li>4. 10 May 2023</li> <li>5. 10 May 2023</li> </ol>
<b>No. of securities held prior to change</b>	<u>Daniel Ow</u> Nil

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Performance rights (Tranche A)</li> <li>2. Performance rights (Tranche B)</li> <li>3. Performance rights (Tranche C)</li> <li>4. Performance rights (Tranche D)</li> <li>5. Performance Rights (Tranche E)</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1. 100,000</li> <li>2. 150,000</li> <li>3. 175,000</li> <li>4. 225,000</li> <li>5. 275,000</li> </ol>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>1. 100,000 performance rights (Tranche A) issued for nil cash consideration as incentive pursuant to resolution 4(c) of the Notice of General Meeting dated 28 February 2023.</li> <li>2. 150,000 performance rights (Tranche B) issued for nil cash consideration as incentive pursuant to resolution 4(c) of the Notice of General Meeting dated 28 February 2023.</li> <li>3. 175,000 performance rights (Tranche C) issued for nil cash consideration as incentive pursuant to resolution 4(c) of the Notice of General Meeting dated 28 February 2023.</li> <li>4. 225,000 performance rights (Tranche D) issued for nil cash consideration as incentive pursuant to resolution 4(c) of the Notice of General Meeting dated 28 February 2023.</li> <li>5. 275,000 performance rights (Tranche E) issued for nil cash consideration as incentive pursuant to resolution 4(c) of the Notice of General Meeting dated 28 February 2023.</li> </ol> <p>Refer to the Notice of General Meeting dated 28 February 2023 for estimated valuation.</p>

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<b>Daniel Ow</b> 100,000 performance rights (Tranche A) 150,000 performance rights (Tranche B) 175,000 performance rights (Tranche C) 225,000 performance rights (Tranche D) 275,000 performance rights (Tranche E)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<b>Issue of Director Performance Rights as approved by shareholders at the Company's General Meeting held on 31 March 2023.</b>

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
---	----

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.